The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

Summit’s lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Investors were undoubtedly especially glad to see key insiders agree to buy more Summit Therapeutics stock. Together, co-CEOs ...

Summit Therapeutics' ivonescimab shows a significant PFS improvement over pembrolizumab in NSCLC. Read why I'm bearish on ...